Medovex Corporation to Participate in the 10th Annual German Spine Society Meeting
Company and Its German Distributor, Aureus Medical GmbH, to Present DenerveX(TM) System Technology to the Surgical Society December 10-12, 2015 in Frankfurt Germany
ATLANTA, GA -- (Marketwired) -- 10/13/15 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company will be participating at the largest European spine meeting, the 10th Annual German Spine Meeting (DWG), scheduled to take place December 10-12, 2015 in Frankfurt Germany.
The German Spine Society ("DWG") is a one of a kind annual meeting, drawing spine care professionals from Germany and around Europe. Participants will share the latest information, innovative techniques and procedures, best practices, and new technologies in spine surgery.
As part of the Company's European pre-launch strategy, Medovex will co-host the meeting with its German distributor Aureus Medical GmbH, a premier distributor in surgical spine technologies. Together, they will be demonstrating the Company's DenerveX System technology for the first time to the medical society, supported by our European medical advisory board and key opinion leaders Dr. Ritter-Lang (Potsdam, Germany) and Dr. Marting Deeg (Stuttgart, Germany).
The Company's patented DenerveX System, currently in development and not yet commercially available, is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.
The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.
Mr. Manfred Sablowski, Medovex Senior Vice President Sales & Marketing, stated, "We are excited to be participating in DWG 2015 in Germany. As the largest spine society in Europe and the third largest spine market in the world, it is clearly the place to introduce trends in new technologies, much like our DenerveX System technology.
Sablowski continued, "It's the key meeting to connect to German and European practitioners and to collaborate, hear differing perspectives, develop relationships and interact as we continue to proceed in the later stages of the development of our DenerveX technology and begin the pre-launch process. We believe the DWG meeting will prepare us well for our future international launch."
DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
About DWG 2015
A one-of-a-kind meeting, where spine care professionals from Germany, Europe and around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies. The annual meeting provides a unique opportunity for you to learn and gain skills through dynamic and challenging educational programs, the ability to network and build relationships with your colleagues and leading experts in spine care.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Source: Medovex Corporation
Released October 13, 2015